JAMA
Results of STEP trials with semaglutide 2.4mg for obesity management has experts excited about its potential
New England Journal of Medicine
Investigational GLP-1 RA efpeglenatide reduces risk for CV events in patients with type 2 diabetes
ADA Diabetes
Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions
Early Use of Sotagliflozin Provides Benefits for People With Type 2 Diabetes With Chronic Kidney Disease or Heart Failure
Endocrine Practice
New AACE guideline for diabetes technology released
American College of Cardiology
Registry Identifies Key Predictors of Major AFib Events in HCM
Lipid Management in Very High-Risk Patients Post-MI: Applying Real World Evidence to Improve Outcomes - Expert Perspectives
Cardiometabolic Health Congress, 1801 North Military, Suite 200, Boca Raton, Florida 33431, United States, 877.571.4700
Unsubscribe Manage preferences
